TLX Telix Pharmaceuticals Limited

$7.75

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending
Expected on
Report Time: Unknown Release Time
The Whisper Number
Consensus Estimate:
Revenue Estimate:

Latest Earnings Insight

Updated On 1/6/2026

About Telix Pharmaceuticals Limited

Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company is headquartered in North Melbourne, Australia.

Website: https://telixpharma.com

Sector
TECHNOLOGY
Industry
GENERAL
Exchange
NASDAQ
Country
USA
Currency
USD
Fiscal Year End
December
CIK
2007191
Address
NONE
Valuation
Market Cap
$5.23B
P/E Ratio
173.44
PEG Ratio
nan
Price to Book
20.71
Performance
EPS
$0.09
Dividend Yield
Profit Margin
7.62%
ROE
20.50%
Technicals
50D MA
$15.60
200D MA
$15.60
52W High
$30.36
52W Low
$13.61
Fundamentals
Shares Outstanding
335M
Target Price
$20.19
Beta
2.38

TLX EPS Estimates vs Actual

Estimated
Actual

TLX News & Sentiment

Dec 29, 2025 • WLNS 6 News NEUTRAL
Class Action Filed Against Telix Pharmaceuticals Ltd. (TLX) Seeking Recovery for Investors – Contact Levi & Korsinsky
Levi & Korsinsky, LLP has filed a class action securities lawsuit against Telix Pharmaceuticals Ltd. (TLX) on behalf of investors who suffered losses due to alleged securities fraud. The lawsuit claims that Telix overstated the progress of its prostate cancer therapeutic candidates and the quality of its supply chain, leading to materially false and misleading statements. Investors affected between February 21, 2025, and August 28, 2025, have until January 9, 2026, to request lead plaintiff status.
Dec 29, 2025 • ACCESS Newswire BEARISH
Tune Into the SueWallSt Podcast: Telix Pharmaceuticals Ltd. (TLX) Lawsuit Explained
Levi & Korsinsky, LLP has released a podcast detailing a class action securities lawsuit filed against Telix Pharmaceuticals Ltd. The lawsuit, filed on behalf of investors, alleges that Telix Pharmaceuticals made false and misleading statements regarding the progress of its prostate cancer therapeutic candidates and the quality of its supply chain between February 21, 2025, and August 28, 2025. Investors who suffered losses during this period are encouraged to contact Levi & Korsinsky.
Dec 29, 2025 • PR Newswire BEARISH
Class Action Filed Against Telix Pharmaceuticals Ltd. (TLX) - January 9, 2026 Deadline to Join - Contact The Gross Law Firm
A class action lawsuit has been filed against Telix Pharmaceuticals Ltd. (TLX) on behalf of shareholders who purchased stock between February 21, 2025, and August 28, 2025. The lawsuit alleges that Telix overstated progress on prostate cancer therapeutic candidates and the quality of its supply chain. Shareholders have until January 9, 2026, to contact The Gross Law Firm to potentially be appointed as lead plaintiff.
Dec 29, 2025 • www.marketscreener.com BEARISH
TELIX PHARMACEUTICALS LTD. (TLX) Berger Montague Advises Investors to Inquire About a Securities Fraud Class Action
Berger Montague PC has filed a class action lawsuit against Telix Pharmaceuticals Ltd. (NASDAQ: TLX) on behalf of investors who purchased securities between February 21, 2025, and August 28, 2025. The lawsuit alleges that Telix misrepresented its development progress and the reliability of its supply chain, leading to significant losses for investors. Investors have until January 9, 2026, to seek appointment as a lead plaintiff.
Dec 28, 2025 • WRIC ABC 8News BEARISH
January 9, 2026 Deadline Approaching: Join Class Action Against Telix Pharmaceuticals Ltd. (TLX) - Contact Levi & Korsinsky
A class action lawsuit has been filed against Telix Pharmaceuticals Ltd. (NASDAQ: TLX) for alleged securities fraud between February 21, 2025, and August 28, 2025. Investors who suffered losses on their TLX securities are encouraged to contact Levi & Korsinsky, LLP before the January 9, 2026 deadline. The lawsuit claims Telix made false statements regarding its prostate cancer therapeutic candidates and the quality of its supply chain.
Dec 27, 2025 • WSAV-TV BEARISH
Burned by Telix Pharmaceuticals Ltd.? Contact Levi & Korsinsky to SueWallSt And Fight Back
Levi & Korsinsky has filed a class-action lawsuit against Telix Pharmaceuticals Ltd. on behalf of investors who experienced losses due to alleged securities fraud between February 21, 2025, and August 28, 2025. The law firm is encouraging affected investors to contact them for assistance. Levi & Korsinsky has a strong track record of winning high-stakes securities litigation cases.
Sentiment Snapshot

Average Sentiment Score:

-0.542
50 articles with scored sentiment

Overall Sentiment:

Bearish

TLX Reported Earnings

Aug 20, 2025
Jun 30, 2025 (Pre market)
0.0 Surprise
  • Reported EPS: $0.01
  • Estimate: $0.00
  • Whisper:
  • Surprise %: 0.0%
Apr 22, 2025
Mar 31, 2025 (Pre market)
0.09 Surprise
  • Reported EPS: $0.09
  • Estimate: $0.00
  • Whisper:
  • Surprise %: 0.0%
Feb 20, 2025
Dec 31, 2024 (Pre market)
0.06 Surprise
  • Reported EPS: $0.06
  • Estimate: $0.00
  • Whisper:
  • Surprise %: 0.0%
Oct 17, 2024
Sep 30, 2024 (Pre market)
0.0 Surprise
  • Reported EPS: $0.00
  • Estimate: $0.00
  • Whisper:
  • Surprise %: 0.0%

Financials